When Jim Cramer calls a stock a "real stalwart" and adds that he doesn't think it's done, investors tend to listen. The CNBC host and former hedge fund manager recently made that exact remark about Cardinal Health (NYSE: CAH), the Dublin, Ohio-based healthcare services company that has quietly been a reliable performer in a volatile market.
What Cramer Said About Cardinal Health
During a segment on Mad Money, Cramer highlighted Cardinal Health as a company that has consistently delivered. "It's been a real stalwart, and I don't think it's done," he said, signaling confidence in the stock's continued strength. The comment aligns with his broader view that certain healthcare and distribution stocks offer stability in uncertain times.
Why Cardinal Health Qualifies as a Stalwart
Cardinal Health is one of the three largest pharmaceutical distributors in the United States, alongside McKesson and AmerisourceBergen. The company's core business — distributing prescription drugs and medical products to hospitals, pharmacies, and clinics — generates steady, recurring revenue. This makes it less susceptible to economic downturns compared to more cyclical sectors.
The Stock's Recent Performance
Cardinal Health shares have shown resilience over the past year, supported by strong demand for pharmaceuticals and medical supplies. The company has also benefited from its role in distributing COVID-19 vaccines and treatments, though that tailwind has moderated. Analysts have noted that CAH's dividend yield and consistent earnings make it attractive for income-focused investors.
Who Benefits from This Bullish Call
Cramer's endorsement matters most for retail investors looking for relatively safe bets in a choppy market. Cardinal Health's business model — essential, non-discretionary healthcare distribution — provides a buffer against inflation and recession fears. For those seeking dividend income, CAH has a track record of paying and growing its dividend, which adds to its appeal as a "stalwart."
What Cramer's Track Record Suggests
Jim Cramer is known for his energetic stock picks and occasional misses, but his "stalwart" label typically applies to companies with durable competitive advantages. In Cardinal Health's case, the company's scale, distribution network, and long-term contracts with healthcare providers give it a moat that is hard to replicate. Cramer's comment suggests he sees these fundamentals as intact and undervalued.
Confirmed Facts vs What Remains Unclear
Confirmed: Jim Cramer made the statement about Cardinal Health being a "real stalwart" with more room to run. The company is a major pharmaceutical distributor with a strong dividend history.
Unclear: Whether Cramer's comment reflects a specific price target or a short-term trading call. The exact context of the remark (e.g., which Mad Money episode) is not fully detailed in available sources.
Cardinal Health's Competitive Moat
Cardinal Health's moat lies in its massive distribution infrastructure. The company operates a network of warehouses, logistics systems, and relationships with virtually every major drug manufacturer and healthcare provider in the U.S. This scale creates cost advantages that smaller competitors cannot match. Additionally, regulatory barriers and the complexity of pharmaceutical logistics make it difficult for new entrants to challenge the Big Three distributors.
Risks and Balanced View
No stock is without risks. Cardinal Health faces ongoing litigation related to the opioid crisis, which has cost the industry billions in settlements. The company also operates on thin margins typical of distribution businesses, meaning any disruption to supply chains or pricing pressure from customers could hurt profitability. Furthermore, Cramer's bullish call does not guarantee future performance — investors should do their own research.
The Broader Healthcare Distribution Trend
Cardinal Health's story is part of a larger trend: the consolidation and resilience of healthcare distribution. As the U.S. population ages and healthcare spending rises, companies like Cardinal Health, McKesson, and AmerisourceBergen are positioned to benefit from increased demand for prescription drugs and medical supplies. This structural tailwind supports Cramer's view that the stock may not be done yet.
What Investors Should Consider Now
For those intrigued by Cramer's call, the next steps are straightforward: review Cardinal Health's upcoming earnings report, check its dividend history, and assess its valuation relative to peers. Investors should also monitor any developments in opioid litigation and regulatory changes affecting drug pricing. A diversified portfolio approach remains wise.
Future Outlook for Cardinal Health
Looking ahead, Cardinal Health's performance will depend on its ability to manage costs, navigate legal challenges, and capture growth in specialty pharmaceuticals and generics. If the company continues to execute, Cramer's "stalwart" label may prove prescient. However, market conditions and sector-specific risks will ultimately determine whether the stock has truly more room to run.
Our Take
Jim Cramer's comment on Cardinal Health is a reminder that not all market winners are flashy tech stocks. In a world of uncertainty, steady, essential businesses with strong dividends and durable moats deserve attention. While no single analyst call should drive investment decisions, Cardinal Health's fundamentals support the idea that it remains a reliable holding for patient investors. The key is to watch for execution and manage risks accordingly.
Frequently Asked Questions
What did Jim Cramer say about Cardinal Health?
Jim Cramer called Cardinal Health a "real stalwart" and said he doesn't think the stock is done performing, indicating he believes it still has upside potential.
Is Cardinal Health a good stock to buy now?
Cardinal Health offers a strong dividend, steady earnings from essential healthcare distribution, and a durable competitive moat. However, investors should consider risks like opioid litigation and thin margins before buying.
What is Cardinal Health's main business?
Cardinal Health is one of the largest pharmaceutical and medical products distributors in the U.S., serving hospitals, pharmacies, and healthcare facilities with essential supplies and drugs.
Does Cardinal Health pay a dividend?
Yes, Cardinal Health has a history of paying and growing its dividend, making it attractive for income-focused investors seeking reliable returns.
